Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Hepatitis C news

Show

From To
Bridging gaps in hepatitis C awareness and diagnosis

If ever there was an area of healthcare where place-based care could have a major impact on local public health gains it is the identification and treatment of hepatitis C virus (HCV) infected patients. However the same reasons that point to place-based health systems being of value for this condition also make it one of the most difficult challenges to take on. If place-based care can be made to work for treating HCV it can be made to work across the system.

Published
10 February 2017
From
New Local Government Network
Initial HCV test results are false positive in almost half of general population

Nearly half of patients in the general population who test positive for hepatitis C virus (HCV) do not have the disease, according to Dr. Anne Moorman and her associates.

Published
08 February 2017
From
Family Practice News
Slamming booklet uses provocative 'Tom of Finland' images in safer injecting guide for gay men

This publication is adapted from a groundbreaking Dutch publication Slammen Do’s and Don’ts first published by Mainline Foundation in January 2016. The UK edition was adapted by Andrew Preston and Roy Jones, and superbly illustrated in the style of Tom of Finland by Michael Linnell.

Published
06 February 2017
From
Exchange Supplies
HCV eradication in HIV coinfected patients linked to reduced diabetes, chronic renal failure

Eradication of hepatitis C virus infection among patients coinfected with HIV was associated with reductions in diabetes and chronic renal failure in addition to reduced mortality, HIV progression and liver-related events, according to the results of a Spanish cohort study. These findings led investigators to conclude that HIV coinfected patients should receive HCV therapy regardless of their fibrosis stage.

Published
31 January 2017
From
Healio
Report Cites Liver Failure Risk With New Hepatitis C Drugs

A new report questions the safety of some of the new drugs found to cure hepatitis C, in light of findings of liver failure and injury. But hepatitis C virus (HCV) experts say the findings are inconclusive, should be interpreted with great caution, and should not influence prescribing.

Published
31 January 2017
From
Medscape
Final yes from NICE for Gilead’s Epclusa

The National Institute for Health and Care Excellence has now published final guidance endorsing Epclusa as an option for the treatment of adults with chronic hepatitis C genotype 1-6 infection on the NHS in England and Wales.

Published
27 January 2017
From
Pharma Times
Two new hepatitis C therapies fast-tracked in Europe

Two drug combinations from Gilead and AbbVie that could improve treatment of chronic hepatitis C have been granted accelerated review in the EU.

Published
25 January 2017
From
PMLive
Are New Drugs for Hepatitis C Safe? A Report Raises Concerns

Drugs approved in recent years that can cure hepatitis C may have severe side effects, including liver failure, a new report suggests. The number of adverse events appears relatively small, and the findings are not conclusive. But experts said the report was a warning that should not be ignored.

Published
25 January 2017
From
New York Times
Egypt combats hepatitis C epidemic with state-run scheme

Two-year-old programme treats 1m patients following outbreak sparked by dirty needles.

Published
23 January 2017
From
Financial Times
Japan: Hepatitis C drug fakes found in Nara drugstore chain

Counterfeits of the hepatitis C drug Harvoni have been found at a drugstore chain in Nara Prefecture, the health ministry said Tuesday. Harvoni is sold by a Japanese unit of U.S. pharmaceutical firm Gilead Sciences Inc. The ingredients of the counterfeits are now under examination.

Published
18 January 2017
From
The Japan Times
← First12345...122Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.